Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Primary |
Number of additional autoimmune diseases at type 1 diabetes diagnosis |
Will be studied the additional autoimmune diseases to type 1 diabetes listed in the 2018 ISPAD recommendations |
up to 3 weeks after type 1 diabetes diagnosis |
|
Primary |
Type of additional autoimmune diseases at type 1 diabetes diagnosis |
Will be studied the additional autoimmune diseases to type 1 diabetes listed in the 2018 ISPAD recommendations |
up to 3 weeks after type 1 diabetes diagnosis |
|
Secondary |
Characteristics of patients, if additional autoimmune disease is present or absent |
Family and personal history, biological, serological, anthropometrical characteristics at type 1 diabetes diagnostic |
up to 3 weeks after type 1 diabetes diagnosis |
|
Secondary |
Occurence or non-occurence of at least one additional autoimmune diseases during follow-up |
Will be studied the additional autoimmune diseases to type 1 diabetes listed in the 2018 ISPAD recommendations |
From type 1 diabetes diagnostic to last news date, an average of 3 years |
|
Secondary |
Occurence or non-occurence of each type of additional autoimmune disease during follow-up |
Will be studied the additional autoimmune diseases to type 1 diabetes listed in the 2018 ISPAD recommendations, in this outcome studied each one separately |
From type 1 diabetes diagnostic to last news date, an average of 3 years |
|
Secondary |
Presence of antibodies specific to an additional autoimmune disease at type 1 diabetes diagnostic |
Antibodies detected in the serum, antibodies specific to the following autoimmune diseases : Hashimoto (Thyroid peroxidase antibodies, and/or thyroglobulin antibodies) Graves disease (TRAK), coeliac disease (anti-tissue transglutaminase (tTG) antibodies,endomysial antibodies (EMA)), Addison disease ( adrenal antibodies ), autoimmune gastritis (parietal cell antibodies) |
up to 3 weeks after type 1 diabetes diagnosis |
|
Secondary |
Characteristics of patients, if at least one type of antibodies specific to an autoimmune disease is present or absent at type 1 diabetes diagnostic |
Family and personal history, biological, serological, anthropometrical characteristics at type 1 diabetes diagnostic |
up to 3 weeks after type 1 diabetes diagnosis |
|
Secondary |
Characteristics of patients, for each type of antibodies specific to an autoimmune disease, present or absent at type 1 diabetes diagnostic |
Family and personal history, biological, serological, anthropometrical characteristics at type 1 diabetes diagnostic |
up to 3 weeks after type 1 diabetes diagnosis |
|
Secondary |
Occurence or non-occurence of at least one type of antibody specific to an additional autoimmune disease |
Antibodies detected in the serum, antibodies specific to the following autoimmune diseases : Hashimoto (Thyroid peroxidase antibodies, and/or thyroglobulin antibodies) Graves disease (TRAK), coeliac disease (anti-tissue transglutaminase (tTG) antibodies,endomysial antibodies (EMA)), Addison disease ( adrenal antibodies ), autoimmune gastritis (parietal cell antibodies) |
From type 1 diabetes diagnosis to last news date, from 1 to 6 years |
|
Secondary |
Occurence or non-occurence of antibodies specific to each additional autoimmune disease listed in outcome 5 |
Antibodies detected in the serum, antibodies specific to the following autoimmune diseases : Hashimoto (Thyroid peroxidase antibodies, and/or thyroglobulin antibodies) Graves disease (TRAK), coeliac disease (anti-tissue transglutaminase (tTG) antibodies,endomysial antibodies (EMA)), Addison disease ( adrenal antibodies ), autoimmune gastritis (parietal cell antibodies) |
From type 1 diabetes diagnosis to last news date, from 1 to 6 years |
|
Secondary |
Description of the characteristics of all the patients followed in our cohort of pediatric type 1 diabetes |
Family and personal history, biological, serological, anthropometrical characteristics at type 1 diabetes diagnostic, presence of antibodies specific to an additional autoimmune disease, and occurence of additional autoimmune diseases |
Up to 3 weeks after type 1 diabetes diagnosis |
|
Secondary |
Description of the autoimmune characteristics of all the patients followed in our cohort of pediatric type 1 diabetes |
presence of antibodies specific to an additional autoimmune disease, and occurence of additional autoimmune diseases |
during follow-up : From type 1 diabetes diagnosis to last news date, from 1 to 6 years |
|
Secondary |
If detection of antibodies specific to an additional autoimmune disease : delay between detection of these antibodies and diagnosis of the corresponding autoimmune disease |
Antibodies detected in the serum, antibodies specific to the following autoimmune diseases : Hashimoto (Thyroid peroxidase antibodies, and/or thyroglobulin antibodies) Graves disease (TRAK), coeliac disease (anti-tissue transglutaminase (tTG) antibodies,endomysial antibodies (EMA)), Addison disease ( adrenal antibodies ), autoimmune gastritis (parietal cell antibodies) |
From type 1 diabetes diagnosis to last news date, from 1 to 6 years |
|
Secondary |
If patient diagnosed with Hashimoto when type 1 diabetes is diagnosed, proportion of patients with thyroid dysfunction |
Thyroid dysfunction : hormonal dysfunction associated to Hashimoto |
Up to 3 weeks after type 1 diabetes diagnosis |
|
Secondary |
Occurence of thyroid dysfunction in patients with type 1 diabetes and Hashimoto |
Occurence during type 1 diabetes follow-up of thyroid dysfunction in patients with Hashimoto |
From type 1 diabetes diagnosis to last news date, from 1 to 6 years |
|
Secondary |
Proportion of patients with thyroid dysfunction due to Hashimoto needing a specific treatment |
|
Up to 3 weeks after type 1 diabetes diagnosis |
|
Secondary |
Occurence of specific treatment onset in patients followed for type 1 diabetes with thyroid dysfunction due to Hashimoto |
|
From type 1 diabetes diagnosis to last news date, from 1 to 6 years |
|